Demystifying Medicine Video



This video describes what chronic myeloid leukemia (CML) is and discusses the following topics:

  • How CML occurs and what are its underlying mechanisms
  • Statistics regarding CML
  • Current treatments and their effectiveness

[Please complete our feedback form]




References
  • Sawyers, C. L. (1999). Chronic myeloid leukemia. New England Journal of Medicine, 340(17), 1330-1340.
  • O'brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., ... & Lechner, K. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 348(11), 994-1004.
  • Hehlmann, R., Hochhaus, A., & Baccarani, M. (2007). Chronic myeloid leukaemia. The Lancet, 370(9584), 342-350.
  • Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., ... & Talpaz, M. (2001). Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine, 344(14), 1038-1042.
  • Noens, L., Van Lierde, M. A., De Bock, R., Verhoef, G., Zachée, P., Berneman, Z., ... & De Geest, S. (2009). Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood, 113(22), 5401-5411.